U.S. health authorities recommended a pause in the use of Johnson & Johnson ’s Covid-19 vaccine in order to investigate rare but severe cases of blood clots.

The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention announced the move Tuesday, after finding that six women between the ages of 18 and 48 years who got the vaccine had developed blood clots.

A panel of outside experts will meet Wednesday to review the matter for the CDC, while the FDA will also conduct an investigation.

J&J’s vaccine was the third authorized for use in the U.S. It uses the same technology as a vaccine from AstraZeneca PLC and the University of Oxford, not yet authorized in the U.S. that has also been linked to rare cases of blood clots.

Write to Peter Loftus at peter.loftus@wsj.com

This content was originally published here.